Plasma-derived Therapies Market, Global Outlook and Forecast 2023-2030

1 Introduction to Research & Analysis Reports
1.1 Plasma-derived Therapies Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Plasma-derived Therapies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Plasma-derived Therapies Overall Market Size
2.1 Global Plasma-derived Therapies Market Size: 2023 VS 2030
2.2 Global Plasma-derived Therapies Market Size, Prospects & Forecasts: 2023-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Key Plasma-derived Therapies Players in Global Market
3.2 Global Companies Plasma-derived Therapies Product & Technology
4 Plasma-derived Therapies Companies Profiles
4.1 CSL Behring LLC
4.1.1 CSL Behring LLC Company Summary
4.1.2 CSL Behring LLC Business Overview
4.1.3 CSL Behring LLC Plasma-derived Therapies Product Offerings & Technology
4.1.4 CSL Behring LLC Plasma-derived Therapies R&D, and Plans
4.2 Shire
4.2.1 Shire Company Summary
4.2.2 Shire Business Overview
4.2.3 Shire Plasma-derived Therapies Product Offerings & Technology
4.2.4 Shire Plasma-derived Therapies R&D, and Plans
4.3 Bayer
4.3.1 Bayer Company Summary
4.3.2 Bayer Business Overview
4.3.3 Bayer Plasma-derived Therapies Product Offerings & Technology
4.3.4 Bayer Plasma-derived Therapies R&D, and Plans
4.4 Kedrion
4.4.1 Kedrion Company Summary
4.4.2 Kedrion Business Overview
4.4.3 Kedrion Plasma-derived Therapies Product Offerings & Technology
4.4.4 Kedrion Plasma-derived Therapies R&D, and Plans
4.5 Takeda
4.5.1 Takeda Company Summary
4.5.2 Takeda Business Overview
4.5.3 Takeda Plasma-derived Therapies Product Offerings & Technology
4.5.4 Takeda Plasma-derived Therapies R&D, and Plans
4.6 Biotest
4.6.1 Biotest Company Summary
4.6.2 Biotest Business Overview
4.6.3 Biotest Plasma-derived Therapies Product Offerings & Technology
4.6.4 Biotest Plasma-derived Therapies R&D, and Plans
4.7 Octaparma
4.7.1 Octaparma Company Summary
4.7.2 Octaparma Business Overview
4.7.3 Octaparma Plasma-derived Therapies Product Offerings & Technology
4.7.4 Octaparma Plasma-derived Therapies R&D, and Plans
4.8 Bio Products Laboratory (BPL)
4.8.1 Bio Products Laboratory (BPL) Company Summary
4.8.2 Bio Products Laboratory (BPL) Business Overview
4.8.3 Bio Products Laboratory (BPL) Plasma-derived Therapies Product Offerings & Technology
4.8.4 Bio Products Laboratory (BPL) Plasma-derived Therapies R&D, and Plans
4.9 LFB
4.9.1 LFB Company Summary
4.9.2 LFB Business Overview
4.9.3 LFB Plasma-derived Therapies Product Offerings & Technology
4.9.4 LFB Plasma-derived Therapies R&D, and Plans
4.10 Grifols
4.10.1 Grifols Company Summary
4.10.2 Grifols Business Overview
4.10.3 Grifols Plasma-derived Therapies Product Offerings & Technology
4.10.4 Grifols Plasma-derived Therapies R&D, and Plans
5 Sights by Region
5.1 By Region - Global Plasma-derived Therapies Market Size, 2024 & 2030
5.2 By Region - Global Plasma-derived Therapies Revenue, (2024-2030)
5.3 United States
5.3.1 Key Players of Plasma-derived Therapies in United States
5.3.2 United States Plasma-derived Therapies Development Current Situation and Forecast
5.4 Europe
5.4.1 Key Players of Plasma-derived Therapies in Europe
5.4.2 Europe Plasma-derived Therapies Development Current Situation and Forecast
5.5 China
5.5.1 Key Players of Plasma-derived Therapies in China
5.5.2 China Plasma-derived Therapies Development Current Situation and Forecast
5.6 Rest of World
6 Sights by Product
6.1 By Type - Global Plasma-derived Therapies Market Size Markets, 2024 & 2030
6.2 Albumin
6.3 Immunoglobulin
6.4 Factor VIII
6.5 Others
7 Sights by Application
7.1 By Application - Global Plasma-derived Therapies Market Size, 2024 & 2030
7.2 Hemophilia
7.3 Primary Immunodeficiencies (PIDs)
7.4 Idiopathic Thrombocytopenic Purpura (ITP)
7.5 COVID-19
7.6 Others
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer